Quick Answer
Adaptive Biotechnologies Corp reported Operating Income of -$57.12 million for fiscal year 2025.
Adaptive Biotechnologies Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$57.12M | +64.9% |
| 2024 | -$162.55M | +28.4% |
| 2023 | -$227.03M | -13.4% |
| 2022 | -$200.19M | +4.2% |
| 2021 | -$208.97M | -36.7% |
| 2020 | -$152.82M | -94.9% |
| 2019 | -$78.39M | -57.6% |
| 2018 | -$49.76M | -11.9% |
| 2017 | -$44.48M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.29M | +131.5% | +141.1% |
| June 30, 2025 | -$25.04M | +47.1% | +15.4% |
| March 31, 2025 | -$29.60M | +39.3% | +9.3% |
| September 30, 2024 | -$32.63M | +36.0% | +31.0% |
| June 30, 2024 | -$47.32M | +1.0% | +3.0% |
| March 31, 2024 | -$48.76M | +14.7% | +4.3% |
| September 30, 2023 | -$50.96M | -12.2% | -6.6% |
| June 30, 2023 | -$47.82M | +8.9% | +16.4% |
- Adaptive Biotechnologies Corp showed an increase of +64.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Adaptive Biotechnologies Corp’s operating income has declined by 28.4% (from -$44.48 million to -$57.12 million).
- The most recent figure is from Adaptive Biotechnologies Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: